Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of parkinsons disease

Journal of Medicinal Chemistry

Volumn 58, Issue 2, 2015, Pages 718-738

  Jörg, Manuela ^a   May, Lauren T ^a   Mak, Frankie S ^b   Lee, Kiew Ching K ^b   Miller, Neil D ^b   Scammells, Peter J ^a   Capuano, Ben ^a  

^a MONASH UNIVERSITY   (Australia)

^b Singapore Research Centre   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2 (FURAN 2 YL N 5 (PIPERIDIN 4 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZINE 5,7 DIAMINE; 2 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY] N [3 [[2 (2 OXOINDOLIN 4 YL)ETHYL](PROPYL)AMINO]PROPYL]ACETAMIDE; 2 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY] N [4 OXO [4 [[3 [[2 (2 OXOINDOLIN 4 YL)ETHYL](PROPYL)AMINO]PROPYL]AMINO]BUTYL]BUTANAMIDE; 3 [12 [4 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY]BUTANAMIDO]DODECANAMIDO] N [2 (2 OXOINDOLIN 4 YL)ETHYL] N PROPYLPROPAN 1 AMINIUM 2,2,2 TRIFLUOROACETIC ACID; 3 [4 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY]BUTANAMIDO] N [2 (2 OXOINDOLIN 4 YL)ETHYL N PROPYLPROPAN 1 AMINIUM 2,2,2 TRIFLUOROACETIC ACID; 4 [2 (2 OXOINDOLIN 4 YL)ETHYL] 1,4 DIAZEPAN 1 IUM 2,2,2 TRIFLUOROACETATIC ACID; 4 [2 (4 AMINOPIPERIDIN 1 YL)ETHYL]INDOLIN 2 ONE; 4 [2 (PIPERAZIN 1 YL)ETHYL]INDOLIN 2 ONE; 4 [2 [4 [7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]PIPERAZIN 1 YL]ETHYL]INDOLIN 2 ONE; 4 [2 [4 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]PIPERIDIN 1 YL]ETHYL]INDOLIN 2 ONE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 [2 [[3 [[4 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY] 6 MORPHOLINO 1,3,5 TRIAZIN 2 YL]AMINO]PROPYL](PROPYL)AMINO]ETHYL]INDOLIN 2 ONE DIFORMIC ACID; 4 [2 [[3 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]PROPYL](METHYL)AMINO]ETHYL]INDOLIN 2 ONE; 4 [2 [[3 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]PROPYL](PROPYL)AMINO]ETHYL]INDOLIN 2 ONE; 4 [2 [[6 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]HEXYL](PROPYL)AMINO]ETHYL]INDOLIN 2 ONE; 4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL](PROPYL)AMINO]ETHYL]INDOLIN 2 ONE; 8 [4 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY]BUTANAMIDO] N [3 [[2 (2 OXOINDOLIN 4 YL)ETHYL(PROPYL)AMINO]PROPYL]OCTANAMIDE; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LIGAND; METHYL 12 [4 [4 [2 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]ETHYL]PHENOXY]BUTANAMIDO]DODECANOIC ACID; N 5 [4 [[4 CHLORO 6 MORPHOLINO 1,3,5 TRIAZIN 2 YL)OXY]PHENETHYL] 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZINE 5,7 DIAMINE; ROPINIROLE; TERT BUTYL 4 [2 (2 OXOINDOLIN 4 YL)ETHYL] 1,4 DIAZEPANE 1 CARBOXYLIC ACID; TERT BUTYL 4 [2 (2 OXOINDOLIN 4 YL)ETHYL]PIPERAZINE 1 CARBOXYLIC ACID; TERT BUTYL 4 [[7 AMINO 2 (FURAN 2 YL)[1,2,4]TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YL]AMINO]PIPERIDINE 1 CARBOXYLIC ACID; TERT BUTYL [1 [2 (2 OXOINDOLIN 4 YL)ETHYL]PIPERIDIN 4 YL]CARBAMIC ACID; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CARBON NUCLEAR MAGNETIC RESONANCE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC50; LIGAND BINDING; MALE; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; AGONISTS; ANIMAL; CHO CELL LINE; CRICETULUS; SYNTHESIS; WISTAR RAT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; CHO CELLS; CRICETULUS; DOPAMINE AGONISTS; LIGANDS; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2;

EID: 84921529971     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501254d     Document Type: Article

References (51)

1. Nussbaum, R. L.; Ellis, C. E. Alzheimers disease and Parkinsons disease N. Engl. J. Med. 2003, 348, 1356-1364
2. Samii, A.; Nutt, J. G.; Ransom, B. R. Parkinsons disease Lancet 2004, 363, 1783-1793
3. Hickey, P.; Stacy, M. Available and emerging treatments for Parkinsons disease: a review Drug Des. Dev. Ther. 2011, 5, 241-254
4. Poewe, W.; Mahlknecht, P.; Jankovic, J. Emerging therapies for Parkinsons disease Curr. Opin. Neurol. 2012, 25, 448-459
5. Hornykiewicz, O. Dopamine miracle: from brain homogenate to dopamine replacement Movement Disord. 2002, 17, 501-508
6. Fahn, S. The history of dopamine and levodopa in the treatment of Parkinsons disease Movement Disord. 2008, 23, 497-508
7. Hauser, R. A. Levodopa: past, present, and future Eur. Neurol. 2009, 62, 1-8
8. Tan, E.-K.; Jankovic, J. Choosing dopamine agonists in Parkinsons disease Clin. Neuropharmacol. 2001, 24, 247-253
9. 2A receptor antagonists and Parkinsons disease: state of the art and future directions Curr. Pharm. Des. 2008, 14, 1475-1489
10. 2A receptor antagonism and dyskinesia in Parkinsons disease Parkinsons Dis. 2012, 489853-489861
11. 2A receptor antagonists for Parkinsons disease Expert Opin. Invest. Drugs 2009, 18, 1619-1631
12. 2A adenosine receptor antagonists in the therapy of Parkinsons disease Pharmacol. Ther. 2011, 132, 280-299
13. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinsons disease Neurotoxic. Res. 2001, 3, 545-556
14. 2A receptor antagonists in Parkinsons disease Pharmacol. Ther. 2005, 105, 267-310
15. Berque-Bestel, I.; Lezoulach, F.; Jockers, R. Bivalent ligands as specific pharmacological tools for G-protein coupled receptor dimers Curr. Drug Discovery Technol. 2008, 5, 312-318
16. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands targeting GPCRs ChemMedChem 2011, 6, 963-974
17. 2 receptor heteromers J. Med. Chem. 2009, 52, 5590-5602
18. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651
19. 2A receptor antagonists Bioorg. Med. Chem. 2003, 11, 1299-1310
20. 2A receptors and monoamine oxidase B by 4 H -3,1-benzothiazin-4-ones J. Med. Chem. 2013, 56, 4580-4596
21. 2 affinity and potency ACS Med. Chem. Lett. 2012, 3, 991-996
22. 2 receptor antagonists EP 459702, May 23, 1991.
23. 2A antagonist, ZM 241385 Struct. Chem. 2013, 24, 1241-1251
24. 2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217
25. Gallagher, G., Jr. 4-Aminoalkyl-2(3 H)-indolones. US4452808A, 1984.
26. De, M. C.; Sree, H. N. Ropinirole and domperidone for use in the treatment of Parkinsons disease. WO9200735A1, 1992.
27. Horvath, J.; Fross, R. D.; Kleiner-Fisman, G.; Lerch, R.; Stalder, H.; Liaudat, S.; Raskoff, W. J.; Flachsbart, K. D.; Rakowski, H.; Pache, J.-C.; Burkhard, P. R.; Lang, A. E. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists Movement Disord. 2004, 19, 656-662
28. Müller, T.; Fritze, J. Fibrosis associated with dopamine agonist therapy in Parkinsons disease Clin. Neuropharmacol. 2003, 26, 109-111
29. 2 receptor functionalized congeners and homobivalent ligands Med. Chem. Commun. 2014, 5, 891-898
30. Jörg, M.; Headey, S.; Scammells, P. J.; Capuano, B. NMR case study of ropinirole: concentration-dependent effects of nonexchangeable proton resonances Magn. Reson. Chem. 2014, 52, 715-718
31. 2A receptor antagonists for extending into extracellular space Bioorg. Med. Chem. Lett. 2013, 23, 3427-3433
32. 2A adenosine receptor antagonists with improved water solubility J. Med. Chem. 2011, 54, 877-889
33. 2-selective adsorption Chem. - Eur. J. 2013, 19, 10573-10579
34. Castelar, S.; Barbera, J.; Marcos, M.; Romero, P.; Serrano, J.-L.; Golemme, A.; Termine, R. Supramolecular dendrimers based on the self-assembly of carbazole-derived dendrons and triazine rings: liquid crystal, photophysical and electrochemical properties J. Mater. Chem. C 2013, 1, 7321-7332
35. Pal, I.; Mandal, M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes Acta Pharmacol. Sin. 2012, 33, 1441-1458
36. Wu, P.; Hu, Y. Small molecules targeting phosphoinositide 3-kinases MedChemComm 2012, 3, 1337-1355
37. Doan, K. M. M.; Humphreys, J. E.; Webster, L. O.; Wring, S. A.; Shampine, L. J.; Serabjit-Singh, C. J.; Adkison, K. K.; Polli, J. W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 2002, 303, 1029-1037
38. Begley, D. J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol. Ther. 2004, 104, 29-45
39. 3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinsons disease J. Med. Chem. 2010, 53, 2114-2125
40. Doll, M. K. H.; Nichols, D. E.; Kilts, J. D.; Prioleau, C.; Lawler, C. P.; Lewis, M. M.; Mailman, R. B. Synthesis and dopaminergic properties of benzo-fused analogs of quinpirole and quinelorane J. Med. Chem. 1999, 42, 935-940
41. 2 dopamine receptors J. Med. Chem. 2000, 43, 3005-3019
42. 1 full agonist J. Med. Chem. 1990, 33, 1756-1764
43. 2 post-synaptic receptor agonist Eur. J. Pharmacol. 1997, 323, 27-36
44. Gobert, A.; Dekeyne, A.; Millan, M. J. The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572 Neuropharmacology 2000, 39, 1608-1616
45. Hitchcock, S. A. Blood-brain barrier permeability considerations for CNS-targeted compound library design Curr. Opin. Chem. Biol. 2008, 12, 318-323
46. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; Osuna, M. d. C.; Hammond, B.; Tang, S.-P.; Hersey, A.; Spalding, D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain J. Pharmacol. Exp. Ther. 2006, 316, 1282-1290
47. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623
48. Bergström, C. A. S.; Charman, S. A.; Nicolazzo, J. A. Computational prediction of CNS drug exposure based on a novel in vivo dataset Pharm. Res. 2012, 29, 3131-3142
49. Ghose, A. K.; Herbertz, T.; Hudkins, R. L.; Dorsey, B. D.; Mallamo, J. P. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery ACS Chem. Neurosci. 2012, 3, 50-68
50. 2A receptors: past, present and future trends for the treatment of Parkinsons disease Curr. Med. Chem. 2014, 21, 2188-2210
51. Hayler, J. D.; Howie, S. L. B.; Giles, R. G.; Negus, A.; Oxley, P. W.; Walsgrove, T. C.; Walsh, S. E.; Dagger, R. E.; Fortunak, J. M.; Mastrocola, A. Some synthetic approaches to ropinirole (SK&F 101468-A): a potent dopamine receptor agonist J. Heterocycl. Chem. 1995, 32, 875-882